Search | Clinical Trials Finder

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, Disease-modifying antirheumatic drug; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 41
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more

Conditions: Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Hemet, California • DeBary, Florida • Venice, Florida + 9 more

Conditions: Rheumatoid Arthritis
Interventions: Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cell, Cyclosporine, Sirolimus, Busulfan, Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection; Radiation · Drug · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 1 Year to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 3
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Osteosarcoma, Metastasis
Interventions: Methotrexate, Doxorubicin, Cisplatin, Gefitinib, Trametinib, Disulfiram, Sunitinib, Ifosfamide, Biopsy; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 6 Years to 49 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Uveitis
Interventions: Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab); Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 52
States / cities: Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 42
States / cities: Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more

Conditions: Rheumatoid Arthritis
Interventions: Golimumab 100 mg, Golimumab 50 mg, Methotrexate, Placebo injection, Placebo capsules; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 13
States / cities: Mobile, Alabama • Palo Alto, California • Pasadena, California + 10 more

Conditions: Psoriasis
Interventions: adalimumab, MTX, placebo adalimumab, placebo MTX; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, Methotrexate, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 59
States / cities: Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more

Conditions: Rheumatoid Arthritis
Interventions: ABT-494, Placebo, Tofacitinib; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Miami, Florida • Cincinnati, Ohio • Duncansville, Pennsylvania + 2 more

Conditions: Rheumatoid Arthritis
Interventions: PLX3397; Drug
Lead sponsor: Plexxikon; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Tuscaloosa, Alabama • Little Rock, Arkansas • San Francisco, California + 2 more

Conditions: Stage IV Breast Cancer, Recurrent Breast Cancer
Interventions: antineoplaston A10, methotrexate, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, chemotherapy, complementary and alternative therapy, differentiation therapy; Drug · Procedure
Lead sponsor: Burzynski Research Institute; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], methotrexate, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 21
States / cities: Santa Monica, California • Upland, California • Whittier, California + 18 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 32
States / cities: La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more

Conditions: Ulcerative Colitis
Interventions: ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo; Drug
Lead sponsor: Abivax S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: San Diego, California • Decatur, Georgia • Austin, Texas + 1 more

Conditions: Rheumatoid Arthritis
Interventions: etanercept pre-filled syringe subcutaneous injection, Oral methotrexate, Placebo for etanercept subcutaneous injection, Placebo for methotrexate, Folic acid (non-investigational product); Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 74
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 68 more

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165, Placebo, MTX, Folic (or folinic) acid; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 45
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Rheumatoid Arthritis
Interventions: Meriva, placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab, Methotrexate; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 46
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more

Conditions: Early Rheumatoid Arthritis
Interventions: adalimumab, methotrexate; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 30
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more

Search by objective public record fields.

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

Curcuma Longa L in Rheumatoid Arthritis

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)